Biocorp Production

Biocorp Production EBIT/Assets

Delisted

The Operating Income to Assets Ratio (EBIT/Assets) of Biocorp Production (ALCOR.PA) as of Oct 30, 2026 is -6.75 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was 1.29 % — a change of -623.02% (lower).

EBIT/Assets

-6.75 %

YoY

-623.02%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Biocorp Production is 2022 -6.75 % . Operating Income to Assets Ratio (EBIT/Assets) of Biocorp Production was 2021 1.29 % . It decreases by -623.02% lower compared to the previous year.

The Biocorp Production EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2015
-24.54 EUR
Jan 1, 2016
-43.19 EUR
Jan 1, 2017
-149.46 EUR
Jan 1, 2018
-103.70 EUR
Jan 1, 2019
12.92 EUR
Jan 1, 2020
-13.71 EUR
Jan 1, 2021
1.29 EUR
Jan 1, 2022
-6.75 EUR
The Biocorp Production EBIT/Assets history
YEAREBIT/AssetsYoY
-6.75 %-623.02%
1.29 %-109.41%
-13.71 %-206.11%
12.92 %-112.46%
-103.70 %-30.62%
-149.46 %+246.06%
-43.19 %+75.99%
-24.54 %-48.83%
-47.96 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biocorp Production Stock analysis

What does Biocorp Production do? Biocorp Production SA is a French company in the medical technology industry that manufactures innovative solutions for drug administration and injections. It was founded in 2004 under the name Biocorp sur mesure by Eric Dessertenne and later transformed into Biocorp Production SA. The business model of Biocorp Production SA is to produce innovative medical devices that can be used in medical applications. The company specializes in the development of smart devices that support injection administration. The devices produced by Biocorp can be operated by medical professionals or by patients themselves. One of the core areas of Biocorp Production SA is the development of smart medical technologies that aid in medication management. One such product is Vyoo, a device that assists patients in injecting medications. It is a digital device that facilitates injection administration and makes dosing safer. In addition to developing smart devices, Biocorp also offers other services, such as in the field of clinical trials for medical applications. The company works closely with pharmaceutical companies to develop medical devices and solutions for drug administration. Another important product is Mallya, an intelligent insulin administration system specifically designed for diabetes patients. It enables automated insulin administration tailored to the patient's needs, thereby improving their quality of life. Furthermore, Biocorp Production SA is also involved in the field of wearable medical technology. One example of a wearable device is Easylog, an electronic device for monitoring medical conditions. This device is particularly useful for patients with chronic diseases such as diabetes or asthma. Over the years, Biocorp Production SA has received numerous awards for its innovative products and services. For example, the company received the Innovation Award at the "Innovation Awards" in Paris in 2017 for the Mallya device. Overall, the company currently employs over 60 employees and has its headquarters in Issoire. It has branches in Germany and the USA. The products of Biocorp Production SA are sold in more than 80 countries worldwide. In summary, Biocorp Production SA is a leading provider of smart medical devices for drug administration and injections. The company strives to develop innovative solutions for the medical industry that are tailored to the needs of patients and medical professionals. With the products of Biocorp Production SA, medication administration becomes safer, easier, and more accurate. Biocorp Production is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biocorp Production stock

Operating Income to Assets Ratio (EBIT/Assets) of Biocorp Production is -6.75 % in 2022.

Operating Income to Assets Ratio (EBIT/Assets) of Biocorp Production changed from 1.29 % to -6.75 %, representing a -623.02% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Biocorp Production since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Biocorp Production with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Biocorp Production

All Key Metrics — Biocorp Production